Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
Qiagen N.V. (QGEN) delivers essential molecular testing solutions powering advancements in healthcare, research, and applied sciences. This dedicated news hub provides investors and professionals with authoritative updates on Qiagen's innovations in sample preparation, automated diagnostics, and bioinformatics.
Access real-time announcements including earnings reports, regulatory milestones, and strategic partnerships. Our curated collection features press releases on product launches, clinical study collaborations, and technology integrations across molecular diagnostics and life sciences.
Key updates cover Qiagen's expanding portfolio for precision medicine, infectious disease testing, and next-generation sequencing workflows. Track developments in critical areas like companion diagnostics and laboratory automation solutions serving global healthcare providers and research institutions.
Bookmark this page for streamlined access to Qiagen's official communications. Stay informed about the company's progress in transforming biological insights into actionable results across 40+ countries.
QIAGEN announced that its QIAstat-Dx syndromic testing solution will soon be available in Japan for detecting over 20 respiratory diseases from a single patient sample. This launch follows IVD approval and is expected in mid-2023, pending reimbursement decisions. With over 3,500 QIAstat-Dx instruments installed globally by the end of 2022, the system is designed for easy operation and provides actionable results in about one hour using PCR technology. The QIAstat-Dx platform allows for multiplex real-time PCR testing and unique access to Ct values and amplification curves, aiding clinical decision-making. >QIAstat-Dx connects to the QIAsphere cloud-based platform for remote monitoring, enhancing diagnostic capabilities across hospitals and labs.
QIAGEN has announced the appointment of Steve Rusckowski to its Supervisory Board. He will stand for election at the Annual General Meeting on June 22, 2023. Rusckowski is a prominent healthcare executive, previously serving as the Chairman, President, and CEO of Quest Diagnostics. He brings extensive experience from his leadership roles, including his tenure at Philips Healthcare. Lawrence Rosen, Chair of the Supervisory Board, expressed confidence that Rusckowski's expertise will contribute to QIAGEN’s future success, especially in navigating a challenging macroeconomic environment. QIAGEN is a global leader in providing solutions for molecular insights from biological samples, serving over 500,000 customers worldwide across various sectors.
FAQ
What is the current stock price of Qiagen (QGEN)?
What is the market cap of Qiagen (QGEN)?
